These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26715881)

  • 1. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
    Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
    Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
    Kiadaliri AA; Eliasson B; Gerdtham UG
    Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
    Karlsson JA; Nilsson JÅ; Neovius M; Kristensen LE; Gülfe A; Saxne T; Geborek P
    Ann Rheum Dis; 2011 Dec; 70(12):2163-6. PubMed ID: 21859684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of EQ-5D-3L health utility scores using five country-specific tariffs in a rural population aged 45-69 years in Hua county, Henan province, China.
    Wang H; Cao C; Guo C; He Y; Li F; Xu R; Liu M; Liu Z; Pan Y; Liu F; Liu Y; Li J; Cai H; He Z; Ke Y
    Health Qual Life Outcomes; 2020 Jul; 18(1):228. PubMed ID: 32660494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
    Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
    Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
    van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
    Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EQ-5D Scores for Diabetes-Related Comorbidities.
    Sullivan PW; Ghushchyan VH
    Value Health; 2016 Dec; 19(8):1002-1008. PubMed ID: 27987626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 Jul; 8(4):627-640. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis.
    Wailoo A; Alava MH; Pudney S; Barton G; O'Dwyer J; Gomes M; Irvine L; Meads D; Sadique Z
    Value Health; 2021 Apr; 24(4):568-574. PubMed ID: 33840435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
    Yang F; Devlin N; Luo N
    Eur J Health Econ; 2019 Feb; 20(1):99-105. PubMed ID: 29948432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of EQ-5D-5L health state utilities using four country-specific tariffs on a breast cancer patient sample in mainland China.
    Liu L; Li S; Wang M; Chen G
    Patient Prefer Adherence; 2017; 11():1049-1056. PubMed ID: 28706443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
    Little MH; Reitmeir P; Peters A; Leidl R
    Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
    Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
    Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
    Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
    Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries.
    Konerding U; Elkhuizen SG; Faubel R; Forte P; Malmström T; Pavi E; Janssen MF
    Health Qual Life Outcomes; 2014 Dec; 12():181. PubMed ID: 25479769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjustment of foreign EQ-5D-3L utilities can increase their transferability.
    Oddershede L; Petersen KD
    Clinicoecon Outcomes Res; 2015; 7():629-36. PubMed ID: 26719715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
    Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
    Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.